The Bladder Cancer Company

About Us

Our Values

Our History

Bladder cancer challenge

Board of directors

Executive Leadership

Leadership

Our Company

Photocure Technology

Our products

Research support

Innovation & Products

News

Bladder Cancer and AI

Addressing Inequality

Our Perspective

Patient Registries And Real-World Evidence

Bladder cancer community support

Corporate social responsibility

ESG Report

Our Impact

Why Partner with Photocure

Our Partners

Partners

Photocure culture

Working at Photocure

Careers

Contact

Events & Presentations

Financials

Shareholder information

FAQs

Investors hub

Investors

Press & Media

Privacy Policy

Terms of use

cevira

Medical congresses & events

Financial Investment & Stock

Photocure ASA: Results for the third quarter of 2024

Medical Information

Partnership News & Expansion

Cevira in Cervical HSIL: Asieris Announces Presentation of Data at the 2024 IPVC Conference Highlighting the Clearance Rate for Different HPV Types 

Photocure ASA: Invitation to presentation of third quarter 2024 financial results

Product Announcements

Photocure Partner Asieris announces Marketing Approval by the National Medical Products Administration for Hexvix in China

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

New publication: blue light cystoscopy shows potential to facilitate the diagnosis of CIS in the upper urinary tract

Photocure ASA: Results for the second quarter of 2024

Photocure ASA: Invitation to presentation of second quarter and first half year 2024 financial results

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Real World Evidence

New Photocure White Paper:  Beyond the buzzwords – How AI and advancing diagnostic technologies will transform early bladder cancer care

Organisational Announcements

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Photocure ASA – Annual general meeting held

Photocure ASA: Results for the first quarter of 2024

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Photocure ASA: Invitation to presentation of first quarter 2024 financial results

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure ASA – Notice of the Annual General Meeting 23 May 2024

Photocure ASA: Annual Report 2023

Patient Registries

Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy

Photocure ASA – Share option grant

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Investor conferences

Photocure to Participate in the 23[rd] Annual Needham Virtual Healthcare Conference

EAU 2024: Photocure Partner Asieris to present the Drug and Equipment Performance Results from the Chinese Phase III Clinical Study of Hexvix in Combination with HD 4K Blue Light Cystoscopy equipment

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Canadian Health Authorities approve updated and expanded label for Cysview

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Photocure ASA: Results for the fourth quarter of 2023

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

New Photocure White Paper addressing Inequality in Bladder Cancer Care and the importance of Real World Evidence

Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024

Photocure Partner Asieris to present unpublished clinical trial and real-world data on Hexvix in China at ASCO GU 2024

SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Photocure to present at four investor conferences in November/December 2023

Photocure ASA: Results for the third quarter of 2023

New publication: immunological impact of Blue Light Cystoscopy with hexaminolevulinate in bladder cancer

Photocure ASA: Invitation to presentation of third quarter 2023 financial results

Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress

Photocure Partner Asieris to present first results for its Hexvix Phase III clinical trial in China at the SIU 2023 Annual Meeting

New Health Economic analysis in France concludes there is insignificant cost difference between White Light and Blue Light Cystoscopy use when applying ccAFU guidelines

Photocure ASA: Change of Board Composition

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Photocure Bladder Cancer Roadshow in Germany & Austria: 2nd edition informs patients and professionals

Photocure ASA: Notification of primary insider transaction

Photocure Partner Asieris confirms Hexvix Phase III clinical trial in China meets endpoint

Photocure ASA: Results for the second quarter and first half of 2023

Photocure ASA: Invitation to presentation of second quarter and first half year 2023 financial results

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

New publication reinforces the clinical benefits of Blue Light Cystoscopy demonstrating an improvement in detection of CIS

Photocure ASA: Results for the first quarter of 2023

Photocure ASA – Correction: Annual general meeting held

New Publication: clinical data demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC 

Photocure ASA: Invitation to presentation of first quarter 2023 financial results

Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light Cystoscopy

Photocure ASA – Notice of the Annual General Meeting 3 May 2023

Photocure ASA: Annual Report 2022

Photocure provides update on Karl Storz’s commitment to maximize the commercial adoption of Saphira™ and decision to discontinue flexible BLC tower production in the U.S.

Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer

Photocure ASA: Results for the fourth quarter of 2022

Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2022 financial results

New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement

Bladder Cancer: New Meta-analysis

Photocure Partner Asieris announces First Patient treated in Hexvix Real-world Evidence study in Hainan, China

Photocure to participate in the NALSC and DNB Healthcare Conferences in December

New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting

Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting

Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China

Photocure ASA: Results for the third quarter of 2022

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC

Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology

Photocure appoints Anders Neijber, MD, PhD as Chief Medical Officer, Global Medical Affairs and Clinical Development

Photocure ASA: Results for the second quarter of 2022

Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

Photocure ASA: Invitation to presentation of second quarter and first half year 2022 financial results

Photocure Provides Update on Anticipated Commercial Availability of Karl Storz’s New Blue Light System in the United States

Photocure Collaborations at EAU Support the Latest Advancements in Bladder Cancer Technology

Photocure ASA: Share capital increase registered

Positive Data from the Danish National Patient Registry presented at the 2022 Nordic Urologisk Forening (NUF) Congress in Helsinki

Photocure partner Asieris announces publication of Cevira study protocol on BMJ Open

Photocure ASA: Exercise of employee share options

Photocure ASA: Acquisition of own shares under the share buy-back program for incentive scheme

Photocure ASA: Exercise of employee share options and share capital increase

Photocure ASA - Initiation of a share buyback

Blue Light Cystoscopy continues to make news at AUA 2022

Photocure ASA: Results for the first quarter of 2022

Photocure ASA: Invitation to presentation of first quarter 2022 financial results

<p>We use cookies to provide the best possible experience for you. By closing this message you agree to our use of cookies. You can learn more about cookies on our <a href="https://photocure.com/privacy-policy" target="_blank" rel="nofollow noopener noreferrer">privacy page</a>.</p>

agree

We value your feedback. Let us know what you think.

Take our survey: provide your feed-back in under 2 minutes

News

E-mail: info@photocure.no

E-mail: info@photocure.com

E-mail: kontakt@photocure.com